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Background  :  This  study  examined  whether  defects  in  insulin  secretion  contribute  to  the  development  and 
progression  of  type  2  diabetes  mellitus  (T2DM). 
Methods  :  Plasma  insulin  and  glucose  were  measured  after  a  glucose  tolerance  test  to  calculate  the  insulinogenic 
index  (IGI)  and  the  HOMA-IR  Homeostasis  model  assessment  of  insulin  resistance  in  subjects  with  normal  glucose 
tolerance  (NGT),  prediabetes  (preDM,  n=49),  and  T2DM  patients  with  disease  duration  <1  year  (n=84),  1～5  years 
(n=45),  or  >5  years  (n=37).  Plasma  proinsulin  and  adiponectin  levels  were  also  measured  as  a  parameter  of  insulin 
secretion  and  resistance. 
Results  :  The  mean  HOMA-IR  increased  and  the  adiponectin  levels  decreased  relative  to  the  deterioration  of 
glucose  tolerance  in  NGT  and  preDM  subjects.  However,  differences  in  the  HOMA-IR  were  not  related  to  disease 
duration  in  T2DM  subjects.  The  mean  IGI  was  similar  in  NGT  and  preDM  subjects,  but  there  were  significant 
deteriorations  in  IGI  relative  to  the  duration  of  diabetes. 
Conclusions  :  Defects  in  both  insulin  sensitivity  and  insulin  secretion  contribute  to  T2DM,  but  decreased  insulin 
secretion  may  be  more  important  in  the  development  and  progression  of  T2DM.
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INTRODUCTION
Several  metabolic  problems  are  associated  with  the 
development  of  type  2  diabetes  (T2DM).  In  particular,  insulin 
resistance  and  decreased  insulin  secretion  contribute  to  the 
pathogenesis  of  T2DM
1).  Insulin  resistance  is  a  decrease  in  the 
endogenous  sensitivity  to  insulin  action.  Endogenous  insulin 
secretion  suppresses  hepatic  glucose  biosynthesis,  increases 
glucose  uptake  and  glycogen  synthesis  in  target  cells,  and 
reduces  the  lipolysis  of  adipocytes
2, 3).  However,  increased 
insulin  resistance  impedes  normal  insulin  activity,  leading  to 
hyperinsulinemia  and,  eventually,  T2DM
4-6).
Deteriorating  insulin  secretion  results  from  β cell  dysfunction 
due  to  glucotoxicity,  lipotoxicity,  βcell  exhaustion,  or  impaired 
proinsulin  biosynthesis
7).  Deteriorating  insulin  secretion  is  seen  in 
all  T2DM  patients,  particularly  in  the  early  phase
8, 9). 
In  fact,  decreased  insulin  secretion  and  increased  insulin 
resistance  precede  the  development  of  clinical  hyperglycemia
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Thus,  early  T2DM  shows  increases  in  endogenous  insulin  levels 
with  increasing  insulin  resistance,  maintaining  normal  glucose 
tolerance.  However,  progressive  reductions  in  insulin  secretion 
eventually  cannot  compensate  for  insulin  resistance,  and 
progresses  to  T2DM
11). 
Deteriorating  insulin  secretion  may  be  actually  be  required  for 
T2DM  development,  since,  at  least  theoretically,  increased 
insulin  production  could  always  compensate  for  increases  in 
insulin  resistance.  Therefore,  here  we  measured  indices  for 
insulin  resistance  and  insulin  secretion  in  Korean  prediabetic 
and  T2DM  subjects  using  an  oral  glucose  tolerance  test,  and 
then  compared  these  indices  according  to  the  severity  of 
glucose  tolerance  and  disease  duration.
MATERIALS AND METHODS
Study  Subjects
This  study  was  performed  from  May  2002  to  September 
2003,  inclusive,  on  251  subjects  with  suspected  or  established 
T2DM  at  the  Department  of  Endocrinology  and  Metabolism, 
Kyung  Hee  University  Hospital.  A  physical  examination  and  oral 
glucose  tolerance  test  (OGTT)  were  performed  on  all  subjects. 
Patients  with  a  fasting  plasma  glucose  ≥11.1  mmol/L  (200 
mg/dL)  were  excluded  from  the  study  population  to  rule  out 
insulin  secretory  dysfunction  due  to  severe  glucotoxicity. 
Methods
In  all  subjects,  the  height,  weight,  body  mass  index,  waist 
circumference,  resting  blood  pressure,  etc.  were  measured.  The 
OGTT  was  performed  after  a  minimum  of  8  hours  fasting,  and 
fasting  plasma  glucose  (Glc0),  insulin  (Ins0),  C-peptide  (Cpep0) 
and  plasma  proinsulin  and  adiponectin  concentrations  were 
measured  to  gauge  β cell  function  and  insulin  resistance.  After 
administering  75  g  glucose  orally,  the  plasma  glucose 
concentration  was  measured  at  30,  60,  90,  and  120  minutes 
(Glc30,  Glc60,  Glc90,  Glc120),  and  plasma  insulin  (Ins30)  and 
C-peptide  (Cpep30)  concentrations  were  measured  30  minutes 
after  glucose  administration.  Plasma  glucose  levels  were 
measured  using  a  Biosen  analyzer  (Biosen  5030;  EKF- 
diagnostic  GmbH,  Magdeburg,  Germany)  and  plasma  insulin 
(Daiichi  RI  Co.,  Tokyo,  Japan),  C-peptide  (Daiichi  RI  Co.), 
adiponectin  (Linco  Research,  MO,  USA),  and  proinsulin  (Linco 
Research)  were  measured  using  commercially  available 
radioimmunoassay  kits.
Subjects  were  divided  into  three  groups  according  to  OGTT 
results:  normal  glucose  tolerance  (NGT),  prediabetes  (preDM), 
which  included  impaired  fasting  glucose  (IFG)  and/or  impaired 
glucose  tolerance  (IGT),  and  type  2  diabetes  mellitus  (T2DM). 
The  diagnosis  of  T2DM  was  made  according  to  the  diagnostic 
criteria  of  the  American  Diabetes  Association
12).  We  also 
calculated  insulin  resistance  using  the  OGTT,  HOMA-IR 
Homeostasis  model  assessment  of  insulin  resistance  and  insulin 
secretion  with  the  Insulinogenic  Index  (IGI)  as  follows
13).
HOMA-IR  =  (Ins0  x  Glc0)/22.5
IGI  =  (Ins30  -  Ins0)  /  18(Glc30  -  Glc0)
Ins0  :  fasting  plasma  insulin  (mIU/L)
Ins30  :  insulin  30  min  after  glucose  intake  (mIU/L)
Glc0  :  fasting  plasma  glucose  (mmol/L)
Glc30  :  plasma  glucose  30  min  after  glucose  intake  (mmol/L)
Patients  diagnosed  with  T2DM  were  classified  according  to 
disease  duration;  less  than  1  year  (DM  <1  yr),  1～5  years  (DM 
1～5  yr),  or  over  5  years  (DM  >5yr).  Therefore,  we  had  a  total 
of  5  subgroups,  NGT,  preDM,  DM  <1  yr,  DM  1～5  yr,  and  DM 
>5  yr  for  comparing  insulin  resistance  and  insulin  secretion.  For 
subjects  taking  oral  hypoglycemic  agents  or  insulin,  a  2-day 
drug  rest  period  was  allowed  prior  to  the  OGTT  to  minimize  the 
effect  of  the  drugs.
Statistical  Analysis
The  Statistical  Package  for  Social  Science  (SPSS,  Version 
13.0;  SPSS  Inc.,  Chicago,  IL,  USA)  was  used  for  statistical 
analysis.  The  Student's  t  test,  one  way  ANOVA,  ANCOVA,  and 
chi-square  tests  were  used.
RESULTS
Clinical  Characteristics
Of  the  251  subjects,  36,  49,  and  166  were  diagnosed  as 
NGT,  preDM,  and  T2DM,  respectively.  There  were  84,  45,  and 
37  patients  with  DM  <1  yr,  1～5  yrs,  and  >5  years,  respectively 
(Table  1).
There  was  no  significant  difference  between  the  subgroups 
according  to  gender,  but  age  and  waist  circumference  showed 
an  increasing  trend  with  lower  glucose  tolerance.  However, 
waist  circumference  showed  this  trend  because  the  waist 
circumference  of  the  NGT  group  was  extremely  low.  The  post 
hoc  test  and  ANOVA  excluding  the  NGT  group  showed  no 
statistically  significant  differences  between  the  groups  (p=0.775).
Subgroup  analysis  of  insulin  resistance  and  insulin 
secretion 
In  each  group,  the  IGI  and  plasma  adiponectin  concentration 
decreased  significantly  with  increasing  glucose  tolerance,  and 
the  HOMA-IR  and  plasma  proinsulin  concentration  increased 
significantly  with  increasing  glucose  tolerance  (Table  2).  There The  Korean  Journal  of  Internal  Medicine  :  Vol.  22,  No.  4,  December  2007 272
NGT
n=36
preDM
N=49
DM  <1  yr
n=84
DM  1～5  yr 
n=45
DM  >5  yr
n=37
p
Age  (years)
Gender  (M/F)
BMI  (kg/m
2)
AC  (cm)
Glc0  (mmol/L)
Glc120  (mmol/L)
47.5±13.6
13  /  23
23.8±3.6
83.6±8.5
5.18±0.63
6.32±1.35
53.0±9.7
22  /  27
25.6±3.4
88.8±8.9
5.64±0.52
9.22±1.10
51.4±11.5
40  /  44
26.7±10.1
88.3±8.6
7.32±1.63
14.79±3.66
56.0±8.7
23  /  22
24.9±2.9
89.2±7.7
7.74±1.77
16.85±3.52
56.5±9.6
19  /  18
24.3±2.4
87.1±7.9
8.62±3.46
18.31±3.46
0.001
0.669
0.121
0.026
<0.001
<0.001
Chi-square  and  ANOVA,  Mean  S.D.
NGT  indicates  normal  glucose  tolerance;  preDM,  prediabetes;  DM,  diabetes  mellitus;  BMI,  body  mass  index;  AC,  abdominal 
circumference;  Glc0,  fasting  plasma  glucose;  Glc120,  plasma  glucose  concentration  2  hours  after  glucose  intake
Table  1.  Clinical  Characteristics  of  Study  Subjects
1)  Plain  Data
NGT
n=36
preDM
n=49
DM  <1  yr
n=84
DM  1～5  yr
  n=45
DM  >5  yr
n=37
p
IGI
HOMA-IR
Proinsulin  (pmol/L)
Adiponectin  (ng/mL)
1.09±1.25
1.29±0.76
11.39±9.11
5201.2±2871.1
0.95±1.09
1.79±0.83
19.48±22.05
4005.0±3642.5
0.22±0.21
3.09±2.14
26.43±16.46
2564.3±2094.2
0.17±0.17
3.06±3.19
31.91±17.09
2541.6±1272.1
0.12±0.15
3.26±1.97
25.66±14.11
2639.5±1880.3
<0.001
<0.001
<0.001
<0.001
ANOVA,  Mean±S.D.
Table  2.  Crude  and  adjusted  geometric  means  of  differences  in  insulin  secretion  and  insulin  resistance  indices
NGT
n=36
preDM
n=49
DM  <1  yr
n=84
DM  1～5  yr 
n=45
DM  >5  yr
n=37
p
IGI
HOMA-IR
Proinsulin  (pmol/L)
Adiponectin  (ng/mL)
1.11±0.12
1.49±0.34
12.16±2.87
5234.8±414.3
0.94±0.10
1.73±0.28
19.28±2.39
4040.5±345.5
0.20±0.08
3.05±0.22
26.34±1.83
2641.3±264.4
0.17±0.10
3.00±0.30
31.62±2.52
2476.2±363.6
0.15±0.11
3.33±0.33
25.75±2.78
2464.6±401.0
<0.001
<0.001
<0.001
<0.001
ANCOVA,  Mean±S.E.
NGT  indicates  normal  glucose  tolerance;  preDM,  prediabetes;  DM,  diabetes  mellitus;  IGI,  insulinogenic  index;  HOMA,  homeostasis  of 
model  assessment
2)  Data  adjusted  for  age  and  abdominal  circumference
was  no  change  in  statistical  significance  after  adjusting  for 
specific  co-variants  that  might  mediate  an  effect  on  insulin 
resistance  or  insulin  secretion.  However,  indices  of  insulin 
resistance  and  insulin  secretion  did  not  show  a  linear 
relationship  with  the  exacerbation  of  glucose  tolerance  or 
increased  disease  duration.  For  example,  IGI  was  similar  in  the 
NGT  and  the  preDM  groups,  and  decreased  with  increasing 
T2DM  disease  duration  (Figure  1).  Although  HOMA-IR 
increased  with  increasing  glucose  tolerance,  the  trend  was  only 
significant  after  adjusting  for  age  and  abdominal  circumference 
by  ANCOVA.  Adiponectin,  but  not  proinsulin,  showed  a 
significant  change  after  adjusting  for  covariances  in  the  NGT 
and  the  preDM  groups  (p=0.006).  Neither  proinsulin  and 
adiponectin  levels  were  associated  with  T2DM  disease  duration 
(data  not  shown).
DISCUSSION
Increased  insulin  resistance  and  deterioration  of  insulin 
secretion  contribute  to  T2DM,  but  their  interaction  and  role  in 
disease  progression  is  unclear
14, 15).  Although  certain  patho-
physiology  and  clinical  features  in  T2DM  are  similar  regardless 
of  ethnicity,  Koreans  more  frequently  have  non-obese  T2DM 
than  Caucasians,  and  the  absolute  number  of  β cells  is  lower, 
meaning  that  insulin  deficiency  usually  plays  a  more  important 
role  than  insulin  resistance
16, 17).  These  differences  suggest  that 
specific  treatment  guideline  for  Korean  patients  may  be  required, 
especially  since  appropriate  treatment  may  dramatically 
influence  the  clinical  course  of  the  disease. 
This  study  examined  a  large  number  of  patients,  as  well  as 
multiple  indices  (adiponectin,  proinsulin,  the  HOMA-IR  and  IGI) 
in  different  Korean  prediabetic  and  T2DM  patients  to  compare 
differences  in  insulin  resistance  and  insulin  secretion.  Fasting Sang  Youl  Rhee,  et  al  :  Differences  in  Insulin  sensitivity  and  secretion  based  on  OGTT 273
 
Figure  1.  Differences  in  insulin  secretion  capacity  (IGI)  and  the  insulin  resistance  index  (HOMA-IR)  according  to  glucose  tolerance  or 
T2DM  duration.  Changes  in  IGI  were  not  significant  in  NGT  and  preDM  subjects  but  decreased  progressively  with  disease  duration, 
whereas  HOMA-IR  values  progressively  increased  with  glucose  tolerance  aggravation,  but  did  not  change  with  disease  duration. 
plasma  adiponectin  levels  are  relatively  independent  of  changes 
in  insulin  secretion,  but  decreased  with  increasing  insulin 
resistance
18-20).  In  addition,  β cell  dysfunction  leads  to  decreased 
cleavage  of  the  insulin  precursor,  which  could  be  assessed  by 
increased  levels  of  proinsulin  and  its  derivatives
21).
Our  results  showed  that  IGI  decreased  and  proinsulin  levels 
increased  with  increasing  glucose  intolerance,  indicating  the 
presence  of  deficient  insulin  secretion.  IGI  was  noticeably  lower 
in  T2DM  than  the  NGT  and  preDM  groups,  and  decreased 
continuously  with  T2DM  duration.  In  contrast  HOMA-IR 
increased  and  adiponectin  levels  decreased  with  increasing 
glucose  tolerance,  indicating  insulin  resistance.  Although  there 
was  a  significant  difference  in  HOMA-IR  and  adiponectin 
between  the  NGT  group  and  the  preDM  groups,  there  was  no 
further  significant  change  after  T2DM  manifestation.  Thus, 
insulin  secretion  from  β cells  seems  relative  well  preserved  in 
preDMs.  However,  T2DM  patients  did  not  show  further 
increases  in  insulin  resistance,  but  did  show  decreased  insulin 
secretion.  These  results  suggest  that  decreased  insulin 
secretion  is  more  significant  than  increases  in  insulin  resistance 
in  Koreans.
In  obese  subjects  with  NGT,  decreased  β cell  function  and 
insulin  secretion  were  not  associated  with  insulin  resistance  or 
decreased  insulin  sensitivity
22).  Thus,  increased  insulin  resistance 
and  decreased  insulin  secretion  do  not  always  progress 
simultaneously,  which  might  explain  the  trends  in  IGI  and 
HOMA-IR  observed  in  this  study. 
One  limitation  of  our  study  is  that  changes  in  insulin 
resistance  and  insulin  secretion  was  not  compared  over  time  in 
the  same  subject.  Our  subgroups  also  were  relatively  small,  and 
the  preDM  group  was  not  further  subdivided.  Although 
HOMA-IR  and  IGI  are  reasonable  measures  of  insulin 
resistance  and  insulin  secretion,  the  insulin  clamp  and  IVGTT 
are  more  accurate.  In  general,  adiponectin,  proinsulin,  and  other 
laboratory  markers  were  consistent  with  the  IGI  and  HOMA-IR 
results,  although  with  some  variability.
Despite  these  limitations,  our  data  still  illuminate  the 
pathophysiology  of  insulin  resistance  and  secretion  in  Korean 
prediabetics  and  type  2  diabetes  patients.  In  particular,  the 
decrease  in  insulin  secretion  seems  more  important  in  the 
progression  and  exacerbation  of  diabetes  than  insulin  resistance. 
However,  a  future  prospective  study  to  overcome  the  limitations 
of  this  study,  as  well  as  a  molecular  biological  study,  will  be 
needed  to  further  clarify  the  changes  in  insulin  resistance  and 
secretion  in  the  pathophysiology  of  early  phase  T2DM.
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